Uncategorized

BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions

Published

3 weeks ago

on

Recorded at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with BioAge co-founder and CEO Kristen Fortney on aging biology, inflammation and why BioAge believes its oral NLRP3 inhibitor could have applications across multiple diseases.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version